Sputnik V COVID-19 vaccine candidate appears safe and effective.
Sputnik V COVID-19 vaccine candidate appears safe and effective.
复制标题
DOI：
10.1016/s0140-6736(21)00191-4
复制
发表时间：
2021-02-20
期刊：
影响因子：
--
通讯作者：
Roy P
中科院分区：
文献类型：
--
作者：
Jones I;Roy P
Denis Logunov 及其同事1 在《柳叶刀》上报告了 Sputnik V COVID-19 疫苗 3 期试验的中期结果。试验结果显示，所有参与者年龄组都具有一致的强大保护作用。该疫苗也称为 Gam-COVID-Vac，采用异源重组腺病毒方法，使用腺病毒 26 (Ad26) 和腺病毒 5 (Ad5) 作为载体，表达严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 刺突蛋白。使用两种不同的血清型（间隔 21 天），旨在克服人群中任何预先存在的腺病毒免疫力。 2 迄今为止正在开发的主要新冠疫苗中，只有 Gam-COVID-Vac 采用了这种方法；其他疫苗，例如牛津-阿斯利康疫苗，两种剂量使用相同的材料。早期的埃博拉病毒病疫苗也是由加马利亚国家流行病学和微生物学研究中心（俄罗斯莫斯科）开发的，与此类似，以Ad5和水泡性口炎病毒为载体病毒3，并且两种不同载体的初免加强的一般原理已在实验中得到广泛应用。 4
Denis Logunov and colleagues1 report their interim results from a phase 3 trial of the Sputnik V COVID-19 vaccine in The Lancet. The trial results show a consistent strong protective effect across all participant age groups. Also known as Gam-COVID-Vac, the vaccine uses a heterologous recombinant adenovirus approach using adenovirus 26 (Ad26) and adenovirus 5 (Ad5) as vectors for the expression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The use of two varying serotypes, which are given 21 days apart, is intended to overcome any pre-existing adenovirus immunity in the population. 2 Among the major COVID vaccines in development to date, only Gam-COVID-Vac uses this approach; others, such as the Oxford–AstraZeneca vaccine, use the same material for both doses. The earlier vaccine for Ebola virus disease, also developed at Gamaleya National Research Centre for Epidemiology and Microbiology (Moscow, Russia), was similar, with Ad5 and vesicular stomatitis virus as the carrier viruses, 3 and the general principle of prime boost with two different vectors has been widely used experimentally. 4